

## **Neha Pathak**

---

**From:** Louise Binder <louise.binder49@gmail.com>  
**Sent:** February 11, 2021 2:14 PM  
**To:** PMPRB Consultations / Consultations CEPMB  
**Subject:** Consultation on change to definition of Gap medicines and the timeline for compliance

**Categories:** "Notice and Comment"

The extension for the date of first sale to the new coming into force date of July 1st is reasonable under the circumstances.

The issue of the filing period reduction to one from the previous two is a matter between PMPRB and the manufacturers. Patient groups do not have the information to determine the implications of this proposal.

In general, patient groups' concern is with any changes to the Guidelines that potentially further adversely impact time to access to treatments. We trust that neither of these changes will have that impact.

--

**Louise Binder**  
Health Policy Consultant  
[louise.binder49@gmail.com](mailto:louise.binder49@gmail.com)

on behalf of  
Save Your Skin Foundation  
[www.saveyourskin.ca](http://www.saveyourskin.ca)

and

CONNECTed patient oncology network